When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology (Q24645229)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20056956%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

review article

1 reference

title

When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20056956%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20056956%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

5

Peter J Neumann

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20056956%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

Craig Earle

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20056956%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Chi-Hui Fang

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20056956%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Adi Eldar-Lissai

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20056956%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

language of work or name

English

0 references

publication date

7 January 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20056956%20AND%20SRC:MED&resulttype=core&format=json

Journal of the National Cancer Institute

16 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20056956%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

102

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20056956%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20056956%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

82-88

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20056956%20AND%20SRC:MED&resulttype=core&format=json

Twenty years of cost-effectiveness analysis in medical imaging: are we improving?

16 January 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808348

Bias in published cost effectiveness studies: systematic review

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808348

Costs of cancer care: a view from the centers for Medicare and Medicaid services

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808348

Is the United States ready for QALYs?

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808348

How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808348

Estimates and projections of value of life lost from cancer deaths in the United States

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808348

Economic evaluations of medical care interventions for cancer patients: how, why, and what does it mean?

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808348

Review of Australian health economic evaluation - 245 interventions: what can we say about cost effectiveness?

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808348

Does preventive care save money? Health economics and the presidential candidates

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808348

The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808348

Costs of cancer care in the USA: a descriptive review.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808348

The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808348

Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808348

Interpreting the economic literature in oncology

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808348

European perspective on the costs and cost-effectiveness of cancer therapies

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808348

Cost of cancer care: issues and implications

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808348

Medicare and cost-effectiveness analysis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808348

Providing guidance to the NHS: The Scottish Medicines Consortium and the National Institute for Clinical Excellence compared

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808348

Growth and quality of the cost-utility literature, 1976-2001.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808348

The price tag on progress--chemotherapy for colorectal cancer

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808348

Systematic overview of cost-utility assessments in oncology

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808348

Public funding of new cancer drugs: Is NICE getting nastier?

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808348

Watchdog set to reject four drugs for kidney cancer on the NHS.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808348

Cancer drugs offer hope, but at huge expense

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808348

Cost-effectiveness versus cost-utility analysis of interventions for cancer: does adjusting for health-related quality of life really matter?

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2808348

Limits on Medicare's ability to control rising spending on cancer drugs

28 November 2018

1 reference

12 December 2020

Year 2006 update of the National List of Health Services--an endless process

1 reference

12 December 2020

A global comparison regarding patient access to cancer drugs

1 reference

12 December 2020

Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand

1 reference

12 December 2020

Why Medicare has not established criteria for coverage decisions

1 reference

12 December 2020

NICE and the challenge of cancer drugs

1 reference

12 December 2020

Identifiers

DOI

10.1093/JNCI/DJP472

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20056956%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20056956%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference